Equity Profile

CAI

Caris Life Sciences, Inc.

Health CareBiotechnology$4.8B

Feb15Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced molecular profiling services to help guide cancer treatment decisions....

Key Metrics to Watch

Molecular Profiling Tests Conducted

This metric indicates the demand for Caris's services and could reflect growth in their customer base.

N/A

Revenue Growth

Revenue growth is a key indicator of the company's market performance and acceptance of its services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced molecular profiling services to help guide cancer treatment decisions. As part of the health care sector, its work is crucial in the ongoing fight against cancer, leveraging data and technology to improve patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In Q1-2026, Caris reported an EPS of $0.00, surprising analysts who expected a loss. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating earnings expectations. However, the lack of analyst estimates creates uncertainty.

Bull Case

If Caris continues its trend of positive surprises, it could signal strong demand for its services and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or reports rising costs without corresponding revenue growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the total number of molecular profiling tests conducted this quarter?

This number will provide insight into the demand for Caris's services and its growth trajectory.

How are operating expenses trending in relation to revenue?

Understanding the relationship between expenses and revenue will help gauge the company's efficiency and profitability outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Caris to expand its market share in molecular profiling, especially given recent trends in personalized medicine.

Supporting Evidence

Caris has consistently beaten earnings expectations, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

The company's recent focus on expanding its service offerings could lead to increased demand that is not fully reflected in current estimates.

Key Risk

If the number of molecular profiling tests conducted exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on how well Caris can manage costs while growing its service offerings in a competitive environment.

Bull Confirmed If

A significant increase in molecular profiling tests conducted, indicating strong demand and potential revenue growth.

Bear Confirmed If

A rise in operating expenses without corresponding revenue growth, suggesting inefficiencies.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests the stock could rise by around 0.82%, confirming strong demand and operational efficiency.

In-Line / Cautious

An in-line result may lead to muted reactions, as management commentary could drive uncertainty about future growth.

Miss

If the company misses expectations, the stock could decline, potentially reflecting concerns over demand or rising costs.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the number of molecular profiling tests conducted this quarter.
2Any updates on new service offerings or partnerships.
3Insights into cost management strategies and operating expenses.
4Management's outlook on market demand for precision medicine.
5Responses to competitive pressures in the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Scorpio Tankers Inc.

Company Snapshot

Caris Life Sciences, Inc. is a biotechnology company focused on precision medicine, providing advanced molecular profiling services to help guide cancer treatment decisions....

Key Metrics to Watch

Molecular Profiling Tests Conducted

This metric indicates the demand for Caris's services and could reflect growth in their customer base.

N/A

Revenue Growth

Revenue growth is a key indicator of the company's market performance and acceptance of its services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In Q1-2026, Caris reported an EPS of $0.00, surprising analysts who expected a loss. The stock reacted positively, gaining 3.71% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's history of beating earnings expectations. However, the lack of analyst estimates creates uncertainty.

Bull Case

If Caris continues its trend of positive surprises, it could signal strong demand for its services and effective cost management, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or reports rising costs without corresponding revenue growth, it could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the total number of molecular profiling tests conducted this quarter?

This number will provide insight into the demand for Caris's services and its growth trajectory.

How are operating expenses trending in relation to revenue?

Understanding the relationship between expenses and revenue will help gauge the company's efficiency and profitability outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Caris to expand its market share in molecular profiling, especially given recent trends in personalized medicine.

Supporting Evidence

Caris has consistently beaten earnings expectations, indicating strong operational performance.

The options market is pricing in a larger move than historical averages, suggesting that traders expect significant news.

The company's recent focus on expanding its service offerings could lead to increased demand that is not fully reflected in current estimates.

Key Risk

If the number of molecular profiling tests conducted exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is focused on how well Caris can manage costs while growing its service offerings in a competitive environment.

Bull Confirmed If

A significant increase in molecular profiling tests conducted, indicating strong demand and potential revenue growth.

Bear Confirmed If

A rise in operating expenses without corresponding revenue growth, suggesting inefficiencies.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests the stock could rise by around 0.82%, confirming strong demand and operational efficiency.

In-Line / Cautious

An in-line result may lead to muted reactions, as management commentary could drive uncertainty about future growth.

Miss

If the company misses expectations, the stock could decline, potentially reflecting concerns over demand or rising costs.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the number of molecular profiling tests conducted this quarter.
2Any updates on new service offerings or partnerships.
3Insights into cost management strategies and operating expenses.
4Management's outlook on market demand for precision medicine.
5Responses to competitive pressures in the biotechnology sector.